Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with Systemic Lupus Erythematosus (SLE) according to recognised international classification standards
- People who are 18 years of age or older
- People who have a newly diagnosed form of lupus kidney disease (lupus nephritis), confirmed by a kidney biopsy, showing specific types of kidney involvement (classified as certain grades of kidney damage, with a protein-to-creatinine ratio of at least 1 g/g — confirm with trial site for full details)
- People who agree to the possibility of having a second kidney biopsy at 12 months after joining the trial
- People who are starting a specific treatment plan that includes steroid infusions, daily oral steroids with a tapering schedule, hydroxychloroquine (unless medically unsuitable), blood pressure-protective medications (ACE inhibitors or ARBs), and either mycophenolate mofetil or intravenous cyclophosphamide — with optional add-on treatments in some cases
Who may not be able to join:
- People who have a related kidney condition caused by antiphospholipid syndrome (a separate blood clotting disorder affecting the kidneys)
- People who are pregnant at the time of joining the trial (becoming pregnant during the trial does not automatically lead to removal from the study)
- People for whom a kidney biopsy would be medically unsafe — for example, those with a very low platelet count, uncontrolled high blood pressure, or severe kidney failure
- People who are considered unlikely to follow the required treatment plan consistently
- People who have other medical conditions that could interfere with measuring the trial's results
- People who are unable to read and/or sign the consent form
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ioannis Parodis, MD PhD, Karolinska Institutet
Phone: +46722321322
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete Renal Response (CRR) at month 24 from baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.